Stock Market Reviews

GERN (Geron Corporation) News

Get the latest news, insights, and market updates on GERN (Geron Corporation). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Geron Corporation (GERN) Restructuring to Lower Operating Expenses as it Eyes Profitability in 2026
  Geron Corporation (NASDAQ:GERN) is one of the best multibagger penny stocks to buy right now. On December 11, the company announced a strategic restructuring plan to lower its operating expenses. It plans to reduce its workforce by a third as it aims to streamline operations while maintaining focus on core priorities. The restructuring drive is […]
  Dec 18, 2025 - $GERN
• Praxis tees up another approval filing; Geron turns to layoffs
  “Collaborative discussions” with the FDA encouraged Praxis to submit early next year an approval filing for its epilepsy drug. Elsewhere, Rezolute shares plunged and Centessa announced a new CEO.
  Dec 12, 2025 - $GERN
• Geron Corporation (GERN) Presents New Data at the 67th American Society of Hematology 2025 Annual Meeting
  Geron Corporation (NASDAQ:GERN) is one of the best long-term penny stocks to invest in. Geron Corporation (NASDAQ:GERN) announced on December 8 that new data was presented at the 67th American Society of Hematology (ASH) 2025 Annual Meeting at Orlando, Florida, with the poster and oral presentations collectively adding to the evidence supporting RYTELO’s potential across […]
  Dec 12, 2025 - $GERN
• Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
  Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced a strategic restructuring plan intended to position the Company for long-term value creation for patients and shareholders and improve its
  Dec 11, 2025 - $GERN
• Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS
  Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in lower-risk MDS Long-term follow-up analysis from IMerge supports favorable survival trends and durable clinical benefit in LR-MDS Additional analyses in myelofibrosis and advanced MDS/AML offer important context for understanding the biology of telomera
  Dec 8, 2025 - $GERN
• Geron Corporation (NASDAQ:GERN) is favoured by institutional owners who hold 64% of the company
  Key Insights Given the large stake in the stock by institutions, Geron's stock price might be vulnerable to their...
  Nov 26, 2025 - $GERN
• Wall Street Turns Bullish on Geron Corporation (GERN) amid Rytelo Sales Push Plans
  Geron Corporation (NASDAQ:GERN) is one of the fastest-growing penny stocks to buy now. On November 11 at the Stifel 2025 Healthcare Conference, it reiterated plans to overcome challenges as it seeks to enhance the commercialization of Rytelo, a prescription medication used to treat anemia. The company plans to shift Rytelo’s use to earlier treatment lines. […]
  Nov 24, 2025 - $GERN
• Geron (GERN) Forecasts Profit in Three Years, Revenue Growth Expected to Outpace US Market
  Geron (GERN) remains unprofitable, with net profit margins showing no improvement and annual losses deepening by 14.5% per year over the past five years. Despite this ongoing challenge, forecasts call for a turnaround in the next three years. Earnings are expected to climb 71.87% per year, and revenue is projected to jump 39.2% annually, well ahead of the broader US market’s growth rate. With no major risks flagged and consensus pointing to absolute and relative value upside, investors are...
  Nov 6, 2025 - $GERN
• Geron: Q3 Earnings Snapshot
  FOSTER CITY, Calif. AP) — Geron Corp. GERN) on Wednesday reported a loss of $18.4 million in its third quarter.
  Nov 5, 2025 - $GERN
• Geron (GERN) Reports Q3 Loss, Lags Revenue Estimates
  Geron (GERN) delivered earnings and revenue surprises of 0.00% and -10.03%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025 - $GERN